, the vaccine is still effective
92 medical devices approved: GE, Siemens, Roche, etc.
Time of Update: 2021-07-24
3 Carbohydrate Antigen 125 Detection Kit (Magnetic Particle Chemiluminescence Method) Shandong Kanghua Biomedical Technology Co.
Pioneer Pharmaceuticals Prokalutamide reduces the risk of death in clinical trials for patients with severe new crown by 92%
Time of Update: 2021-07-19
announced that the clinical trial of Prokruamide in Brazil for the treatment of severely ill patients with new crowns reached the primary end point: the WHO new crown rating scale for the treatment group of Proklamide decreased by 4.
The recycling rate of industrial water in Shandong will be increased to 92%
Time of Update: 2021-07-18
By 2020, the province’s reclaimed water utilization rate will reach over 25%, and the newly added seawater desalination capacity will be about 400,000 tons per day.
Oil prices may be stranded for the first time this year, 92 gasoline is still in the "6 yuan era"
Time of Update: 2021-07-04
Li Yan predicts that the global economic outlook is positive, and the probability of the next round of refined oil price adjustments is expected to increase.
agonist and NK cell therapy is expected to enhance the anti-tumor activity of TROP-2 ADC
Time of Update: 2021-06-30
The test mainly evaluates the combination The safety and effectiveness of the therapy in patients with advanced triple-negative breast cancer (TNBC) .
A new target for immunotherapy-NKG2A, which targets NK cells and can act synergistically with PD-1/L1
Time of Update: 2021-06-30
Therefore, the development of new NKG2A antibodies is expected to complement existing immunotherapy and better treat cancer patients .
More than half of the patients achieved complete remission. "Ready-to-use" NK cell therapy has positive early clinical results
Time of Update: 2021-06-22
Recently, Fate Therapeutics announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting that it announced its research on natural killer cell (NK cell) therapy FT516, combined with rituximab, to treat patients with relapsed/refractory B-cell lymphoma.
More than half of ASCO patients achieved complete remission, and early clinical results of "ready-to-use" NK cell therapy were positive
Time of Update: 2021-06-17
related to FT516 were found . "These phase 1 clinical trial data from outpatient administration of FT516 continue to demonstrate its differentiated safety characteristics and its
ASCO 2021: Fate's iPSC-derived NK cell clinical data is active
Time of Update: 2021-06-17
, and the oncolytic virus has entered the fast lane Yimai New Observation Click on the picture and register now June 9, 2021 /Healthcare News eMedClub News/--Fate recently announced the results of a multi-dose phase I clinical trial of FT516 at the 2021 American
Nature: NK cells make tumors dormant
Time of Update: 2021-06-08
Before the metastasis begins to grow, cancer cells may have metastasized from the primary tumor to other sites (a process called metastasis), where they can stay dormant for a long time.
Oil prices may be stranded again during the year. No. 92 gasoline is still in the "6 yuan era"
Time of Update: 2021-06-05
According to statistics from the Sino-Singapore Jingwei Client, since 2021, domestic refined oil prices have been adjusted for nine rounds, with a total increase of RMB 1,005/ton for gasoline and RMB 970/ton for diesel.
5.14-5.20|15 cases of medical and health financing included in the total financing of more than 100 million yuan accounting for 92%
Time of Update: 2021-06-02
(hereinafter referred to as "Huida Gene") recently completed 400 million yuan in Series B financing.
Up to 92% drop in consumables selection results announced: Johnson & Johnson, Xerox Hui, Telif...
Time of Update: 2021-05-23
Insurance Bureau issued the "Announcement on the Results of the Negotiations for the Su Yansu Xutonghuai Public Medical Institutions' Medical Consumables Alliance to Bring Volume Renewal and Expansion", showing:>
The placenta-derived, allogeneic, natural killer NK cell therapy was awarded the FDA orphan drug
Time of Update: 2021-04-23
morbidity and disproportionately high mortality. NK cell therapy for glioblastoma CYNK-001 is placental-derived natural killer (PNK) cells, cryopreservation developed from placental hematopoietic stem cells
Professor Junning Cao: Research Progress of Extranodal NK/T Cell Lymphoma|The 4th China Conference on Individualized Lymphoma Treatment
Time of Update: 2021-04-19
At a median follow-up of 17 months, the 3-year progression-free survival (PFS) rate of NK/T-cell lymphoma patients reached 57.
B cell NHL treatment: Can NK cell immunotherapy combined with chemotherapy and ASCT achieve "off-the-shelf"?
Time of Update: 2021-03-24
and high-dose chemotherapy combined ASCT treatment of B-cell NHL: Nato Y, Kaur I, Hosing C, et al Study Overview:. "Off-the-shelf " Can it be possible
Pioneering pharmaceutical proclosamine treatment of severe new crown patients clinical trial death risk reduced by 92%
Time of Update: 2021-03-22
Hospital stay shortened by 9 days544px;white-space:normal;background-color:#FFFFFF;box-sizing:border-box !important;'> 544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box !important;overflow-wrap:break-word !important;'> Prokalamide treatment group (N=294) Placebo control group (N=296) Number of people percentage Number of people percentage mortality rate 11 3.
2021 EBMT | CAR.CD123-NK cells are expected to bring new treatment strategies for CD123-positive children with AML
Time of Update: 2021-03-21
9%) in vitro, and showed significant anti-leukemia activity against CD123-positive tumor cells (Figure A below) ).